Heuron gets FDA green light for stroke triage and notification solution
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated